These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37219713)

  • 1. Vasopressin V2 receptor antagonists for the syndrome of inappropriate antidiuretic hormone secretion.
    Tanemoto M
    Int Urol Nephrol; 2024 Jan; 56(1):361-362. PubMed ID: 37219713
    [No Abstract]   [Full Text] [Related]  

  • 2. Tolvaptan for Treatment of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) in a Child with Corpus Callosum Agenesis.
    Meena AK; Nanda PM; Sharma R; Chakrabarty B; Gulati S
    Indian J Pediatr; 2024 Feb; 91(2):188-190. PubMed ID: 36757652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of tolvaptan on hyponatremia in a dog with syndrome of inappropriate secretion of antidiuretic hormone.
    Yamamoto H; Kimura K; Horikirizono H; Tamura Y; Kambayashi S; Baba K; Okuda M; Mizuno T; Igase M
    J Vet Med Sci; 2023 Oct; 85(10):1047-1051. PubMed ID: 37587049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vasopressin receptor antagonists: the vaptans].
    Villabona C
    Endocrinol Nutr; 2010 May; 57 Suppl 2():41-52. PubMed ID: 21130961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uric acid levels with tolvaptan treatment for syndrome of inappropriate antidiuretic hormone secretion.
    Nagamine T
    Endocrine; 2024 Mar; 83(3):826-827. PubMed ID: 37982946
    [No Abstract]   [Full Text] [Related]  

  • 6. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
    Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS
    Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current options of treatment of hyponatremia].
    Tesař V
    Vnitr Lek; 2016; 62 Suppl 6():97-101. PubMed ID: 28124939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of vasopressin receptor antagonists in hyponatremia.
    Khanna A; Menon MC
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1007-14. PubMed ID: 20730695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
    Wada K; Matsukawa U; Fujimori A; Arai Y; Sudoh K; Sasamata M; Miyata K
    Biol Pharm Bull; 2007 Jan; 30(1):91-5. PubMed ID: 17202666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The use of tolvaptan in a case of severe hyponatriemia in SIADH during meningitis].
    Rollino C; Balbiano R; Caramello P; Roccatello D
    G Ital Nefrol; 2013; 30(6):. PubMed ID: 24402662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of V2 vasopressin antagonists in hyponatremia.
    Palm C; Reimann D; Gross P
    Cardiovasc Res; 2001 Aug; 51(3):403-8. PubMed ID: 11476730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence in hyponatremia related to inappropriate secretion of ADH that V1 receptor stimulation contributes to the increase in renal uric acid clearance.
    Decaux G; Namias B; Gulbis B; Soupart A
    J Am Soc Nephrol; 1996 May; 7(5):805-10. PubMed ID: 8738818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyponatremia, fluid-electrolyte disorders, and the syndrome of inappropriate antidiuretic hormone secretion: diagnosis and treatment options.
    Siragy HM
    Endocr Pract; 2006; 12(4):446-57. PubMed ID: 16901803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Syndrome of inappropriate antidiuresis without involving inappropriate secretion of vasopressin in an elderly woman: effect of intravenous administration of the nonpeptide vasopressin V2 receptor antagonist OPC-31260.
    Kamoi K
    Nephron; 1997; 76(1):111-5. PubMed ID: 9171309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
    Palm C; Pistrosch F; Herbrig K; Gross P
    Am J Med; 2006 Jul; 119(7 Suppl 1):S87-92. PubMed ID: 16843091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
    Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
    Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolvaptan for SIADH in Myelodysplastic Syndrome with Blast Crisis.
    Mali P; Muduganti SR; Mujibur R; Murali N
    WMJ; 2015 Apr; 114(2):66-8. PubMed ID: 26756059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.
    Bordi P; Tiseo M; Buti S; Regolisti G; Ardizzoni A
    Tumori; 2015 Apr; 101(2):e51-3. PubMed ID: 25702667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BSC1 inhibition complements effects of vasopressin V2 receptor antagonist on hyponatremia in SIADH rats.
    Kazama I; Hatano R; Michimata M; Suzuki K; Arata T; Suzuki M; Miyama N; Sato A; Satomi S; Ejima Y; Sasaki S; Matsubara M
    Kidney Int; 2005 May; 67(5):1855-67. PubMed ID: 15840033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasopressin V2 receptor antagonists.
    Verbalis JG
    J Mol Endocrinol; 2002 Aug; 29(1):1-9. PubMed ID: 12200224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.